or Try an Advanced Search...

    Technical Analysis for KRON - Kronos Bio, Inc.

    Grade Last Price % Change Price Change
    F 0.91 5.83% 0.05
    KRON closed up 1.18 percent on Wednesday, November 20, 2024, on 2.26 times normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical KRON trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 5.83%
    Inside Day Range Contraction 5.83%
    Gapped Up Strength 5.83%
    Volume Surge Other 7.07%
    Outside Day Range Expansion 7.07%
    Volume Surge Other 7.08%
    NR7 Range Contraction 7.08%
    Narrow Range Bar Range Contraction 7.08%
    Inside Day Range Contraction 7.08%
    Down 3 Days in a Row Weakness 7.08%
    Older End-of-Day Signals for KRON ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 3 hours ago
    20 DMA Resistance about 3 hours ago
    Up 5% about 3 hours ago
    Up 3% about 3 hours ago
    Up 1 ATR about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    KRON Chart by TradingView
    Basic chart:

    Profile

    Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Solid Tumors Acute Myeloid Leukemia Enzymes Tyrosine Kinase Transcription Cancer Therapeutics Transcription Factors Novel Cancer Transcription Factor Cyclin Dependent Kinase Entospletinib Morpholines

    Is KRON a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 17 Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
    Nov 16 Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
    Nov 14 Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
    Nov 14 Kronos mulls ‘strategic alternatives’ after axing cancer drug development
    Nov 14 Kronos Bio downgraded by Piper Sandler, TD Cowen
    Nov 14 Kronos Bio  GAAP EPS of -$0.23
    Nov 13 Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
    Nov 13 Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
    Nov 5 Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
    Oct 23 Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
    See more KRON news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.6
    52 Week Low 0.69
    Average Volume 110,463
    200-Day Moving Average 1.05
    50-Day Moving Average 0.94
    20-Day Moving Average 0.91
    10-Day Moving Average 0.87
    Average True Range 0.06
    RSI (14) 42.20
    ADX 30.09
    +DI 8.90
    -DI 21.65
    Chandelier Exit (Long, 3 ATRs) 0.83
    Chandelier Exit (Short, 3 ATRs) 0.97
    Upper Bollinger Bands 1.02
    Lower Bollinger Band 0.81
    Percent B (%b) 0.24
    BandWidth 23.48
    MACD Line -0.03
    MACD Signal Line -0.02
    MACD Histogram -0.0058
    Fundamentals Value
    Market Cap 50.15 Million
    Num Shares 58.3 Million
    EPS -2.08
    Price-to-Earnings (P/E) Ratio -0.41
    Price-to-Sales 15.45
    Price-to-Book 0.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.90
    Resistance 3 (R3) 0.90 0.88 0.89
    Resistance 2 (R2) 0.88 0.87 0.88 0.89
    Resistance 1 (R1) 0.87 0.87 0.87 0.87 0.89
    Pivot Point 0.86 0.86 0.86 0.86 0.86
    Support 1 (S1) 0.85 0.85 0.84 0.85 0.83
    Support 2 (S2) 0.83 0.84 0.83 0.83
    Support 3 (S3) 0.82 0.83 0.83
    Support 4 (S4) 0.82